FDA advisers back Alzheimer's drug to slow disease

By Associated Press

Jun 11, 2024 9:33 am

WASHINGTON, D.C. — A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.

Food and Drug Administration advisers voted unanimously that the drug's ability to slow the disease outweighs its risks, including side effects like brain swelling and bleeding that will have to be monitored.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.

Related Articles

Trump vows to prosecute Google for showing 'bad' stories on him

Israel rebuffs calls for 21-day ceasefire

Pope to meet 15 sexual abuse victims in Belgium

3 killed as Hurricane Helene makes landfall

Trump, Zelenskyy meet over Ukraine conflict

UK's Starmer vows nation to pursue global leadership

'Please don't eat my cat': Trump parody song goes viral